Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial.
Tan DHS, Rolon MJ, Figueroa MI, Sued O, Gun A, Kaul R, Raboud JM, Szadkowski L, Hull MW, Walmsley SL, Cahn P; Argentinean GARDEL research network. Tan DHS, et al. Among authors: figueroa mi. PLoS One. 2019 Sep 6;14(9):e0221653. doi: 10.1371/journal.pone.0221653. eCollection 2019. PLoS One. 2019. PMID: 31490959 Free PMC article.
The effect of protease inhibitor-based dual antiretroviral regimens on CD4/CD8 ratio during the first year of therapy in ART-naïve patients with HIV-infection.
Figueroa MI, Camiro-Zuñiga A, Belaunzaran-Zamudio PF, Sierra Madero J, Andrade Villanueva J, Arribas JR, Lama JR, Cecchini DM, Lopardo G, Crabtree-Ramírez B, Gun A, Patterson P, Fink VI, Sued OG, Cahn P. Figueroa MI, et al. HIV Med. 2021 Apr;22(4):254-261. doi: 10.1111/hiv.13008. Epub 2020 Dec 17. HIV Med. 2021. PMID: 33336523 Free article.
Pre-cART Immune Parameters in People Living With HIV Might Help Predict CD8+ T-Cell Characteristics, Inflammation Levels, and Reservoir Composition After Effective cART.
Salido J, Czernikier A, Trifone C, Polo ML, Figueroa MI, Urioste A, Cahn P, Sued O, Salomon H, Laufer N, Ghiglione Y, Turk G. Salido J, et al. Among authors: figueroa mi. Pathog Immun. 2021 Oct 1;6(2):60-89. doi: 10.20411/pai.v6i2.447. eCollection 2021. Pathog Immun. 2021. PMID: 34988339 Free PMC article.
Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study.
Frola CE, Aristegui I, Figueroa MI, Radusky PD, Cardozo N, Zalazar V, Cesar C, Patterson P, Fink V, Gun A, Cahn P, Sued O. Frola CE, et al. Among authors: figueroa mi. PLoS One. 2023 Jan 20;18(1):e0279996. doi: 10.1371/journal.pone.0279996. eCollection 2023. PLoS One. 2023. PMID: 36662723 Free PMC article. Clinical Trial.
Dual therapy based on co-formulated darunavir/ritonavir plus lamivudine for initial therapy of HIV infection: The ANDES randomized controlled trial.
Figueroa MI, Sued O, Cecchini D, Sanchez M, Rolón MJ, Lopardo G, Ceschel M, Mernies G, De Stefano M, Patterson P, Gun A, Fink V, Ortiz Z, Cahn P; ANDES Study Group. Figueroa MI, et al. Int J Antimicrob Agents. 2024 Oct;64(4):107301. doi: 10.1016/j.ijantimicag.2024.107301. Epub 2024 Aug 14. Int J Antimicrob Agents. 2024. PMID: 39151647 Clinical Trial.
43 results